Anti Osteoporosis Therapy and Fracture Healing Market is Expected to Surpass US$ 12 Bn by the End of 2021

Market

According to the National Osteoporosis Foundation, there has been a substantial increase in osteoporosis incidence among postmenopausal women due to calcium deficiency. This is driving the market for anti-osteoporosis therapy and fracture healing.

Future Market Insights, Dubai: FMI has projected the anti-osteoporosis therapy and fracture healing-market to record a CAGR of 3% through 2030. The demand for anti-osteoporosis therapy and fracture healing treatment is anticipated to continue surging due to the rising demand for non-invasive therapeutics.

Osteoporosis is a chronic and a life-threatening disease in which the microstructure of bones is altered due to reduction in bone mass and bone density. This condition leads to increased bone brittleness and risk of bone fractures and cracks. Thus, osteoporosis is considered life threatening due to severe injury and associated pain. The significant reduction in the bone mass density leads to changes in microstructure of the bones resulting in increased threat of bone cracks and bone fractures. According to the International Osteoporosis Foundation (IOF), osteoporosis is also known as a silent disease because many people do not know they have osteoporosis until they have a fist fracture. Based on an IOF report, each year osteoporosis causes more than 8.9 million fractures and bone cracks across the globe. Furthermore, it is indicated that nearly 200 million women all over the world are being affected by osteoporosis every year.

Key players are adopting merger and acquisition strategies for increasing their presence across the globe,” says the FMI analyst.

Anti-Osteoporosis Therapy And Fracture Healing treatment Market – Important Highlights

  • Bisphosphonates will remain the preferred drug type due to the growing adaptation to target-specific treatments
  • The oral route of administration is expected to remain most preferred
  • Profit from hospital pharmacy is projected to grow by 2X by 2030 compared to 2019.
  • The U.S. is leading the global market for anti-osteoporosis treatment and fracture healing, with revenues estimated to exceed US$ 6.3 billion by 2030

Request a report sample to gain comprehensive market insights at

https://www.futuremarketinsights.com/reports/sample/rep-gb-1008

Anti-Osteoporosis Therapy And Fracture Healing Treatment Market – Drivers

  • Increase in geriatric population, who are at high risk of osteoporosis, is driving the market
  • The increasing pace of drug approval and commercialization are enabling growth
  • Increasing investment in innovation and new product launches are expected to boost the market

 Anti-Osteoporosis Therapy and Fracture Healing Treatment Market – Restraints

  • Significantly less understanding of osteoporosis and its treatment choices in GCC countries is hindering the growth of the market.
  • Poor economic conditions and healthcare infrastructure might hinder the adoption of anti-osteoporosis therapy and fracture healing treatment across some countries

COVID-19 Impact on Anti-Osteoporosis Therapy And Fracture Healing treatment Market

During this time there has been a disruption in the supply and demand chain which has caused an impact on the revenue of the Anti-Osteoporosis Therapy And Fracture Healing treatment in a negative way. However, this is estimated to be a temporary effect and the market is expected to have a turnaround. The pandemic has led to a decrease in the patient’s flow in the hospitals, and doctor chambers. This has caused a reduction in the number of surgeries and that in turn has affected the Anti-Osteoporosis Therapy And Fracture Healing treatment market.

Get Access to Research Methodology Prepared by Experts>>> https://www.futuremarketinsights.com/ask-question/rep-gb-1008

Competitive Landscape

Key companies are aiming at strategic collaboration. The Anti-osteoporosis treatment and fracture healing industry is a relatively consolidated market with fewer than 10 market players comprising more than 50% of the overall revenue.

Some of the leading companies operating in the market are Eli Lilly and Company, Pfizer Inc., Amgen Inc., Merck and Company, Inc., Novartis International AG, F. Hoffmann La Roche Ltd.

About the Study

The study offers readers a comprehensive assessment of the Anti-Osteoporosis Therapy And Fracture Healing treatment market. Global, regional, and national-level analysis of the latest trends influencing the market is covered in this FMI report. The study provides insights based on drug class (Bisphosphonates, Calcitonin, Estrogen or Hormone Replacement Therapy), route of administration (oral, injectable), distribution channel (Hospital Pharmacies, Retail Pharmacies, Online sales), and across key regions (North America, Latin America, Europe, China, Asia Pacific, Middle East & Africa).

Ask For Country-Specific Data https://www.futuremarketinsights.com/ask-country-specific/rep-gb-1008

Explore FMI’s Coverage of the healthcare Industry

Rapid Infuser Market: Get insights on the rapid infuser market through FMI’s report covering detailed quantitative and qualitative analysis for the projection period 2020-2030.

Medical face shield market: FMI’s exhaustive study on the medical face shield market covers the latest trends, innovations, key players, and popular strategies for the period 2020-2030.

laryngoscopes market: Obtain detailed analysis on the Laryngoscopes market through FMI’s report covering competitive analysis, key regions, and segmental analysis for 2020-2030.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:

Future Market Insights,

1602-6 Jumeirah Bay X2 Tower,

Plot No: JLT-PH2-X2A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

For Sales Enquiries: sales@futuremarketinsights.com

For Media Enquiries: press@futuremarketinsights.com

Website: https://www.futuremarketinsights.com/

Report: https://www.futuremarketinsights.com/reports/anti-osteoporosis-therapy-and-fracture-healing-market

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”